These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
221 related articles for article (PubMed ID: 16237500)
21. The role of adjuvants in the development of mucosal vaccines. Vajdy M; Singh M Expert Opin Biol Ther; 2005 Jul; 5(7):953-65. PubMed ID: 16018740 [TBL] [Abstract][Full Text] [Related]
22. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA. Holmgren J; Harandi AM; Czerkinsky C Expert Rev Vaccines; 2003 Apr; 2(2):205-17. PubMed ID: 12899572 [TBL] [Abstract][Full Text] [Related]
23. Toward precision adjuvants: optimizing science and safety. Nanishi E; Dowling DJ; Levy O Curr Opin Pediatr; 2020 Feb; 32(1):125-138. PubMed ID: 31904601 [TBL] [Abstract][Full Text] [Related]
24. Defending the mucosa: adjuvant and carrier formulations for mucosal immunity. Lawson LB; Norton EB; Clements JD Curr Opin Immunol; 2011 Jun; 23(3):414-20. PubMed ID: 21511452 [TBL] [Abstract][Full Text] [Related]
26. Manipulating the immune system: humoral versus cell-mediated immunity. McNeela EA; Mills KH Adv Drug Deliv Rev; 2001 Sep; 51(1-3):43-54. PubMed ID: 11516778 [TBL] [Abstract][Full Text] [Related]
27. Immunity in response to particulate antigen-delivery systems. Storni T; Kündig TM; Senti G; Johansen P Adv Drug Deliv Rev; 2005 Jan; 57(3):333-55. PubMed ID: 15560945 [TBL] [Abstract][Full Text] [Related]
28. Optimizing efficacy of mucosal vaccines. Gebril A; Alsaadi M; Acevedo R; Mullen AB; Ferro VA Expert Rev Vaccines; 2012 Sep; 11(9):1139-55. PubMed ID: 23151169 [TBL] [Abstract][Full Text] [Related]
29. Adjuvants and delivery systems based on polymeric nanoparticles for mucosal vaccines. Jin Z; Gao S; Cui X; Sun D; Zhao K Int J Pharm; 2019 Dec; 572():118731. PubMed ID: 31669213 [TBL] [Abstract][Full Text] [Related]
30. Mucosal immunity: overcoming the barrier for induction of proximal responses. McKenzie BS; Brady JL; Lew AM Immunol Res; 2004; 30(1):35-71. PubMed ID: 15258310 [TBL] [Abstract][Full Text] [Related]
31. Subunit-based mucosal vaccine delivery systems for pulmonary delivery - Are they feasible? Marasini N; Kaminskas LM Drug Dev Ind Pharm; 2019 Jun; 45(6):882-894. PubMed ID: 30767591 [TBL] [Abstract][Full Text] [Related]
32. Jump-starting the immune system: prime-boosting comes of age. Woodland DL Trends Immunol; 2004 Feb; 25(2):98-104. PubMed ID: 15102369 [TBL] [Abstract][Full Text] [Related]
33. Recent advances in vaccine adjuvants for systemic and mucosal administration. O'Hagan DT J Pharm Pharmacol; 1998 Jan; 50(1):1-10. PubMed ID: 9504429 [TBL] [Abstract][Full Text] [Related]
34. Delivery systems and adjuvants for oral vaccines. Lavelle EC; O'Hagan DT Expert Opin Drug Deliv; 2006 Nov; 3(6):747-62. PubMed ID: 17076597 [TBL] [Abstract][Full Text] [Related]
35. New adjuvants for parenteral and mucosal vaccines. Guy B; Burdin N Therapie; 2005; 60(3):235-41. PubMed ID: 16128265 [TBL] [Abstract][Full Text] [Related]